These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 8461561)

  • 1. Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol.
    Neer M; Slovik DM; Daly M; Potts T; Nussbaum SR
    Osteoporos Int; 1993; 3 Suppl 1():204-5. PubMed ID: 8461561
    [No Abstract]   [Full Text] [Related]  

  • 2. [Parathyroid and bone. Role of parathyroid hormone in the treatment of osteoporosis].
    Nakamura T
    Clin Calcium; 2007 Dec; 17(12):1823-9. PubMed ID: 18057656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapy of osteoporosis using the ADFR schedule (especially with parathyroid hormone and etidronate)].
    Ziegler R
    Internist (Berl); 1991 Feb; 32(2):76-9. PubMed ID: 1903362
    [No Abstract]   [Full Text] [Related]  

  • 4. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss.
    Gallagher JC; Fowler SE; Detter JR; Sherman SS
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3618-28. PubMed ID: 11502787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
    Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
    J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination and sequential therapy for osteoporosis.
    Heaney RP; Recker RR
    N Engl J Med; 2005 Aug; 353(6):624-5. PubMed ID: 16093472
    [No Abstract]   [Full Text] [Related]  

  • 7. Daily and cyclic parathyroid hormone in women receiving alendronate.
    Cosman F; Nieves J; Zion M; Woelfert L; Luckey M; Lindsay R
    N Engl J Med; 2005 Aug; 353(6):566-75. PubMed ID: 16093465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
    Black DM; Greenspan SL; Ensrud KE; Palermo L; McGowan JA; Lang TF; Garnero P; Bouxsein ML; Bilezikian JP; Rosen CJ;
    N Engl J Med; 2003 Sep; 349(13):1207-15. PubMed ID: 14500804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PREOS NPS (Allelix/Nycomed).
    White H; Ahmad A
    Curr Opin Investig Drugs; 2005 Oct; 6(10):1057-66. PubMed ID: 16259228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ALX 111: ALX1-11, parathyroid hormone (1-84) - NPS Allelix, PREOS, PTH, recombinant human parathyroid hormone, rhPTH (1-84).
    Adis International Ltd
    Drugs R D; 2003; 4(4):231-5. PubMed ID: 12848587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the combination of alendronate and parathyroid hormone give a greater benefit than either agent alone in osteoporosis?
    Doggrell SA
    Expert Opin Pharmacother; 2004 Apr; 5(4):955-8. PubMed ID: 15102578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Parathyroid and bone. Evidence and perspective of parathyroid therapy for patients with osteoporosis].
    Wada S; Fukawa T; Kamiya S
    Clin Calcium; 2007 Dec; 17(12):1888-94. PubMed ID: 18057665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis.
    Miller PD
    N Engl J Med; 2004 Jan; 350(2):189-92; author reply 189-92. PubMed ID: 14714279
    [No Abstract]   [Full Text] [Related]  

  • 14. Parathyroid hormone(1-84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy.
    Fogelman I; Fordham JN; Fraser WD; Spector TD; Christiansen C; Morris SA; Fox J
    Calcif Tissue Int; 2008 Aug; 83(2):85-92. PubMed ID: 18626566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study.
    Dempster DW; Cosman F; Kurland ES; Zhou H; Nieves J; Woelfert L; Shane E; Plavetić K; Müller R; Bilezikian J; Lindsay R
    J Bone Miner Res; 2001 Oct; 16(10):1846-53. PubMed ID: 11585349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential parathyroid hormone/alendronate therapy for osteoporosis--robbing Peter to pay Paul?
    Horwitz M; Stewart A; Greenspan SL
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2127-8. PubMed ID: 10852439
    [No Abstract]   [Full Text] [Related]  

  • 17. Full length parathyroid hormone, PTH(1-84), for the treatment of severe osteoporosis in postmenopausal women.
    Adami S
    Curr Med Res Opin; 2008 Nov; 24(11):3259-74. PubMed ID: 18940041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
    J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of calcitriol treatment with etidronate-calcitriol and calcitonin-calcitriol combinations in Turkish women with postmenopausal osteoporosis: a prospective study.
    Gürlek A; Bayraktar M; Gedik O
    Calcif Tissue Int; 1997 Jul; 61(1):39-43. PubMed ID: 9192511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis.
    Black DM; Bilezikian JP; Ensrud KE; Greenspan SL; Palermo L; Hue T; Lang TF; McGowan JA; Rosen CJ;
    N Engl J Med; 2005 Aug; 353(6):555-65. PubMed ID: 16093464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.